Answers are grounded in this paper and cite their sources.
: Due to differences in study populations and manufacturing times, it is too early to know if there is a 'best' choice for CAR T-cell therapy. Decisions must be individualized taking into account patient factors and expected toxicity.
No takes yet. Share an insight, caveat, or question.
Hunter et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: